Skip to content

Nasdaq · CIK 0001806310

TSHA Taysha Gene Therapies, Inc.

Insider trading from SEC Form 4. Last filing Jul 10, 2026. Close $4.49 on Oct 9, 2026, +17% from the 52-week low and -36% from the high.

In brief

Taysha Gene Therapies, Inc. (TSHA) has 32 SEC Form 4 filings on file from 8 insiders, the latest filed on Jul 10, 2026. No insider bought or sold on the open market in the last 90 days; rows filed in that time are grants, exercises, tax withholding and other transactions that carry no view on the price.

13 open-market trades have been scored at TSHA. The newest: Sukumar Nagendran (President and Head of R&D) sold $1.2M of stock on Jul 10, 2026, filed Jul 10, 2026, scored 30 (weak), under a 10b5-1 plan. The largest of the 13 shown: Paul B Manning (10% owner) bought $2.1M on May 30, 2025, scored 38 (weak). 3 insiders sold within 14 days of each other around Feb 4, 2026.

24 Form 144 notices of planned sales are on file, the latest filed Jul 10, 2026.

Last 90 days

Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
8
with a Form 4 at this company

Price and insider trades, last year

TSHAOct 9, 2026 · close 4.49

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™

Signals

Open-market buys and sells at Taysha Gene Therapies, Inc., scored.

ScoreInsiderValueHoldingsPrice contextFiled
30WeakSukumar Nagendran
President and Head of R&D
sell
$1.2M
200,000 shares
-18%+153% from low-9% from high
13WeakSukumar Nagendran
President and Head of R&D
sell
$892k
200,000 shares
-15%+284% from low-24% from high
37WeakKamran Alam
CHIEF FINANCIAL OFFICER
sell
$7,481
1,655 shares
-0%+302% from low-23% from high
55ModerateKamran Alam
CHIEF FINANCIAL OFFICER
sell
$485k
102,817 shares
-7%+312% from low-21% from high
54ModerateSukumar Nagendran
President and Head of R&D
sell
$547k
116,050 shares
-8%+312% from low-21% from high
63NotableSean P. Nolan
Chief Executive Officer
sell
$840k
178,101 shares
-6%+312% from low-21% from high
29WeakSukumar Nagendran
President and Head of R&D
sell
$942k
200,000 shares
-17%+330% from low-18% from high
40ModerateSukumar Nagendran
President and Head of R&D
sell
$1.7M
370,172 shares
-33%-
10WeakSukumar Nagendran
President and Head of R&D
sell
$646k
200,000 shares
-17%-
41ModerateKamran Alam
CHIEF FINANCIAL OFFICER
sell
$155k
54,491 shares
-4%-
39WeakSukumar Nagendran
President and Head of R&D
sell
$163k
57,054 shares
-5%-
38WeakPaul B Manning
owner
buy
$2.1M
750,000 shares
+36%-
31WeakPaul B Manning
owner
buy
$163k
100,000 shares
+1%+188% from low-54% from high

Planned sales

Form 144 notices filed before a sale of restricted or control stock, newest first. The sale itself usually reaches a Form 4 within days. All planned sales

FiledSellerSharesValueSale datePast 3 months
Jul 10, 2026 Nagendran Sukumar
Officer
200,000
0.06% of outstanding
$1.3MJul 10, 2026$831k
Apr 10, 2026 Nagendran Sukumar
Officer
200,000
0.07% of outstanding
$926kApr 10, 2026$943k
Feb 27, 2026 Rumana Haque-Ahmed
Officer
2,405
0.00% of outstanding
$11kFeb 27, 2026$148k
Feb 4, 2026 Kamran Alam
Officer
1,655
0.00% of outstanding
$7,812Feb 4, 2026$485k
Feb 4, 2026 Rumana Haque-Ahmed
Officer
697
0.00% of outstanding
$3,290Feb 4, 2026$145k
Feb 4, 2026 Sean McAuliffe
Affiliate - Chief Business Officer
914
0.00% of outstanding
$4,314Feb 4, 2026$222k
Feb 4, 2026 Emily McGinnis
Affiliate-Chief Pat. Adv. & Ext. Aff. Off.
901
0.00% of outstanding
$4,253Feb 4, 2026$154k
Feb 4, 2026 Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
889
0.00% of outstanding
$4,196Feb 4, 2026$264k
Jan 23, 2026 Kamran Alam
Officer
100,846
0.04% of outstanding
$513kJan 23, 2026none
Jan 23, 2026 Rumana Haque-Ahmed
Officer
30,052
0.01% of outstanding
$153kJan 23, 2026none
Jan 23, 2026 Sean McAuliffe
Affiliate - Chief Business Officer
46,064
0.02% of outstanding
$234kJan 23, 2026none
Jan 23, 2026 Emily McGinnis
Affiliate-Chief Pat. Adv. & Ext. Aff. Off.
32,077
0.01% of outstanding
$163kJan 23, 2026none
Jan 23, 2026 Sukumar Nagendran
Officer
113,824
0.04% of outstanding
$579kJan 23, 2026$1.5M
Jan 23, 2026 Sean P. Nolan
Officer, Director
168,078
0.06% of outstanding
$856kJan 23, 2026none
Jan 23, 2026 Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
54,916
0.02% of outstanding
$280kJan 23, 2026none
Jan 12, 2026 Nagendran Sukumar
Officer
200,000
0.07% of outstanding
$996kJan 12, 2026$1.7M
Nov 28, 2025 Nagendran Sukumar
Officer
370,172
0.14% of outstanding
$1.8MNov 28, 2025$646k
Sep 22, 2025 Rumana Haque-Ahmed
Officer
10,770
0.00% of outstanding
$30kSep 22, 2025none
Sep 10, 2025 Nagendran Sukumar
Officer
200,000
0.07% of outstanding
$652kSep 10, 2025$163k
Aug 21, 2025 Kamran Alam
Officer
54,491
0.02% of outstanding
$156kAug 21, 2025none
Aug 21, 2025 Sean McAuliffe
Affiliate - Chief Business Officer
27,590
0.01% of outstanding
$79kAug 21, 2025none
Aug 21, 2025 Emily McGinnis
Affiliate-Chief Pat. Adv. & Ext. Aff. Off.
19,604
0.01% of outstanding
$56kAug 21, 2025none
Aug 21, 2025 Sukumar Nagendran
Officer, Director
57,054
0.02% of outstanding
$164kAug 21, 2025none
Aug 21, 2025 Fred Porter
Affiliate-Chief of Staff & Tech.Op.Officer
50,451
0.02% of outstanding
$145kAug 21, 2025none

Transactions

The newest 50 of 64 rows filed, every code.

DateInsiderTransactionSharesPriceValueHoldings afterFiled
Jul 10, 2026Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock10b5-1
-200,000$6.24$1.2M936,410Jul 10, 2026
Jun 1, 2026Phillip B. Donenberg
director
AGrant or award
Common Stock
+21,335$0.00$0241,289Jun 2, 2026
Jun 1, 2026Alison S Long
director
AGrant or award
Common Stock
+21,335$0.00$0127,178Jun 2, 2026
Jun 1, 2026John A Stalfort III
director
AGrant or award
Common Stock
+21,335$0.00$01,176,559Jun 2, 2026
Jun 1, 2026Laura Sepp-Lorenzino
director
AGrant or award
Common Stock
+21,335$0.00$0127,178Jun 2, 2026
Jun 1, 2026Alison S Long
director
AGrant or award
Stock Option (right to buy)derivative
+42,671$0.00$042,671Jun 2, 2026
Jun 1, 2026Phillip B. Donenberg
director
AGrant or award
Stock Option (right to buy)derivative
+42,671$0.00$042,671Jun 2, 2026
Jun 1, 2026Laura Sepp-Lorenzino
director
AGrant or award
Stock Option (right to buy)derivative
+42,671$0.00$042,671Jun 2, 2026
Jun 1, 2026John A Stalfort III
director
AGrant or award
Stock Option (right to buy)derivative
+42,671$0.00$042,671Jun 2, 2026
Apr 10, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock10b5-1
+19,021$1.71$33k1,336,410Apr 13, 2026
Apr 10, 2026Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock10b5-1
-200,000$4.46$892k1,136,410Apr 13, 2026
Apr 10, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-19,021$0.00$0455,920Apr 13, 2026
Feb 4, 2026Kamran Alam
CHIEF FINANCIAL OFFICER
SOpen-market sale
Common Stock
-1,655$4.52$7,4811,442,131Feb 6, 2026
Jan 23, 2026Kamran Alam
CHIEF FINANCIAL OFFICER
SOpen-market sale
Common Stock
-78,968$4.75$375k1,467,635Jan 27, 2026
Jan 23, 2026Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock
-89,132$4.75$423k1,344,307Jan 27, 2026
Jan 23, 2026Sean P. Nolan
Chief Executive Officer
SOpen-market sale
Common Stock
-136,789$4.75$650k2,949,569Jan 27, 2026
Jan 26, 2026Sean P. Nolan
Chief Executive Officer
SOpen-market sale
Common Stock
-41,312$4.61$190k2,908,257Jan 27, 2026
Jan 26, 2026Kamran Alam
CHIEF FINANCIAL OFFICER
SOpen-market sale
Common Stock
-23,849$4.61$110k1,443,786Jan 27, 2026
Jan 26, 2026Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock
-26,918$4.61$124k1,317,389Jan 27, 2026
Jan 12, 2026Kamran Alam
CHIEF FINANCIAL OFFICER
AGrant or award
Common Stock
+359,000$0.00$01,546,603Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock10b5-1
+111,324$0.70$78k1,117,763Jan 14, 2026
Jan 12, 2026Sean P. Nolan
Chief Executive Officer
AGrant or award
Common Stock
+1,008,000$0.00$03,086,358Jan 14, 2026
Jan 12, 2026Kamran Alam
CHIEF FINANCIAL OFFICER
AGrant or award
Employee Stock Option (right to buy)derivative
+231,000$0.00$0231,000Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock10b5-1
+88,676$1.71$152k1,206,439Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock10b5-1
-200,000$4.71$942k1,006,439Jan 14, 2026
Jan 12, 2026Sean P. Nolan
Chief Executive Officer
AGrant or award
Employee Stock Option (right to buy)derivative
+648,000$0.00$0648,000Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
AGrant or award
Common Stock10b5-1
+427,000$0.00$01,433,439Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-111,324$0.00$0111,359Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-88,676$0.00$0474,941Jan 14, 2026
Jan 12, 2026Sukumar Nagendran
President and Head of R&D
AGrant or award
Employee Stock Option (right to buy)derivative10b5-1
+274,000$0.00$0274,000Jan 14, 2026
Nov 28, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock
+70,172$0.70$49k1,076,611Dec 1, 2025
Nov 28, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock
+39,953$1.71$68k1,116,564Dec 1, 2025
Nov 28, 2025Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock
-110,125$4.75$523k1,006,439Dec 1, 2025
Dec 1, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock
+260,047$1.71$445k1,266,486Dec 1, 2025
Dec 1, 2025Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock
-260,047$4.51$1.2M1,006,439Dec 1, 2025
Nov 28, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative
-70,172$0.00$0222,683Dec 1, 2025
Nov 28, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative
-39,953$0.00$0823,664Dec 1, 2025
Dec 1, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative
-260,047$0.00$0563,617Dec 1, 2025
Sep 10, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Common Stock10b5-1
+41,150$0.70$29k1,206,439Sep 12, 2025
Sep 10, 2025Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock10b5-1
-200,000$3.23$646k1,006,439Sep 12, 2025
Sep 10, 2025Sukumar Nagendran
President and Head of R&D
MOption exercise
Employee Stock Option (right to buy)derivative10b5-1
-41,150$0.00$0292,855Sep 12, 2025
Aug 21, 2025Kamran Alam
CHIEF FINANCIAL OFFICER
SOpen-market sale
Common Stock
-54,491$2.85$155k1,187,603Aug 22, 2025
Aug 21, 2025Sukumar Nagendran
President and Head of R&D
SOpen-market sale
Common Stock
-57,054$2.85$163k1,165,289Aug 22, 2025
Jun 2, 2025Phillip B. Donenberg
director
AGrant or award
Common Stock
+56,623$0.00$0219,954Jun 4, 2025
Jun 2, 2025Alison S Long
director
AGrant or award
Common Stock
+56,623$0.00$0105,843Jun 4, 2025
Jun 2, 2025Laura Sepp-Lorenzino
director
AGrant or award
Common Stock
+56,623$0.00$0105,843Jun 4, 2025
Jun 2, 2025John A Stalfort III
director
AGrant or award
Common Stock
+56,623$0.00$01,155,224Jun 4, 2025
Jun 2, 2025Phillip B. Donenberg
director
AGrant or award
Stock Option (right to buy)derivative
+113,246$0.00$0113,246Jun 4, 2025
Jun 2, 2025Alison S Long
director
AGrant or award
Stock Option (right to buy)derivative
+113,246$0.00$0113,246Jun 4, 2025
Jun 2, 2025Laura Sepp-Lorenzino
director
AGrant or award
Stock Option (right to buy)derivative
+113,246$0.00$0113,246Jun 4, 2025
50 of 64 rows shown.

Insiders

Everyone who has filed a Form 4 here.

Questions about TSHA

Answered from the filings on this page, as of the latest one.

Are insiders buying TSHA?

No. In the last 90 days no insider at Taysha Gene Therapies, Inc. bought or sold shares on the open market according to SEC Form 4 filings. The rows on file from that period are grants, exercises, tax withholding or other transactions, which carry no view on the price.

Who was the last insider to trade TSHA on the open market?

Sukumar Nagendran (President and Head of R&D) sold $1.2M of TSHA on Jul 10, 2026 and filed the Form 4 on Jul 10, 2026. InsiderTell scored 30 (weak), under a 10b5-1 plan.

How many insiders file Form 4 at Taysha Gene Therapies, Inc.?

8 people have filed a Form 4 at Taysha Gene Therapies, Inc., among them Kamran Alam (CHIEF FINANCIAL OFFICER), Phillip B. Donenberg (director), Alison S Long (director). Officers, directors and holders of more than 10% of a share class must report their trades within two business days.

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

TSHA insider trading: Taysha Gene Therapies, Inc. | InsiderTell